The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...
About 1 in 8 men will be diagnosed with prostate cancer in their lifetime The average age at diagnosis is 67 Less than 1% of the 3.5 million men living with prostate cancer are expected to die from it ...
Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of these men will die of causes other than prostate cancer. This is revealed in a ...
A new study provides hope that smarter timing of cancer treatments could improve cure rates. The study's Principal Investigator, Dr Robert Noble, Senior Lecturer at the Department of Mathematics, City ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results